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Clinical Features and Outcome of
Hypertrophic Cardiomyopathy Associated
With Triple Sarcomere Protein Gene Mutations
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Massimo Baldi, MD,† Melissa L. Will, BS,¶ Katia Baldini, RN,† Francesca Torricelli, BS,*
Laura Yeates, BSC,§ Franco Cecchi, MD,† Michael J. Ackerman, MD, PHD,¶ Iacopo Olivotto, MD†
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Objectives The aim of this study was to describe the clinical profile associated with triple sarcomere gene mutations in a
large hypertrophic cardiomyopathy (HCM) cohort.
Background In patients with HCM, double or compound sarcomere gene mutation heterozygosity might be associated with
earlier disease onset and more severe outcome. The occurrence of triple mutations has not been reported.
Methods A total of 488 unrelated index HCM patients underwent screening for myofilament gene mutations by direct de-
oxyribonucleic acid sequencing of 8 genes, including myosin binding protein C (MYBPC3), beta-myosin heavy
chain (MYH7), regulatory and essential light chains (MYL2, MYL3), troponin-T (TNNT2), troponin-I (TNNI3), alpha-
tropomyosin (TPM1), and actin (ACTC).
Results Of the 488 index patients, 4 (0.8%) harbored triple mutations, as follows: MYH7-R869H, MYBPC3-E258K, and
TNNI3-A86fs in a 32-year-old woman; MYH7-R723C, MYH7-E1455X, and MYBPC3-E165D in a 46-year old man;
MYH7-R869H, MYBPC3-K1065fs, and MYBPC3-P371R in a 45-year old woman; and MYH7-R1079Q, MYBPC3-
Q969X, and MYBPC3-R668H in a 50-year old woman. One had a history of resuscitated cardiac arrest, and 3
had significant risk factors for sudden cardiac death, prompting the insertion of an implantable cardioverter-
defibrillator in all, with appropriate shocks in 2 patients. Moreover, 3 of 4 patients had a severe phenotype with
progression to end-stage HCM by the fourth decade, requiring cardiac transplantation (n  1) or biventricular
pacing (n  2). The fourth patient, however, had clinically mild disease.
Conclusions Hypertrophic cardiomyopathy caused by triple sarcomere gene mutations was rare but conferred a remarkably
increased risk of end-stage progression and ventricular arrhythmias, supporting an association between multiple
sarcomere defects and adverse outcome. Comprehensive genetic testing might provide important insights to
risk stratification and potentially indicate the need for differential surveillance strategies based on genotype.
(J Am Coll Cardiol 2010;55:1444–53) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.062m
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Hypertrophic cardiomyopathy (HCM) is the most common
enetic cardiac disease, characterized by heterogeneous
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009, accepted November 2, 2009.orphologic expression and clinical course (1,2). Mutations
n genes coding for myofilament contractile proteins of the
ardiac sarcomere represent the most common genetic
ubtype of HCM, with a prevalence of 30% to 65% in
ohort studies (3–7). Double or compound heterozygosity
See page 1454
i.e., patients with 2 distinct mutations in the same or in
ifferent sarcomere genes) has been described in 3% to 6%
f consecutively screened cohorts and has been associated
ith earlier onset and more severe clinical profile, compared
ith single mutation HCM (8–12). To our knowledge,
CM associated with triple sarcomere mutations has notreviously been reported. In the present study, we describe
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ndex patient harbored 3 distinct mutations in sarcomere
enes.
ethods
atient selection. A total of 488 unrelated index patients
ith a confirmed clinical diagnosis of HCM from 3 referral
enters (Florence, Boston, Sydney) underwent systematic
creening for mutations in 8 myofilament genes, in the period
anuary 2002 to February 2009 (4). The diagnosis, based on
he standard accepted definition for HCM, consisted of
-dimensional echocardiographic identification of a hypertro-
hied, nondilated left ventricle (LV), in the absence of another
ardiac or systemic disease capable of producing the magnitude
f ventricular hypertrophy evident (1,2,13).
utational analysis. Patients were screened for mutations
n the protein-coding exons and splice sites of 8 myofilament
enes, including myosin binding protein C (MYBPC3), thick
lament proteins (beta-myosin heavy chain [MYH7] and the
egulatory and essential light chains [MYL2 and MYL3]), and
hin filament proteins (troponin-T [TNNT2], troponin-I
TNNI3], alpha-tropomyosin [TPM1], and alpha-actin
ACTC]). Direct deoxyribonucleic acid (DNA) sequencing
as employed with either ABI-Prism 3730 (Applied Biosys-
ems, Foster City, California) as previously described (4) or the
CM CardioChip platform (Laboratory for Molecular
edicine, Cambridge, Massachusetts). This latter platform
ncludes a combination of direct sequencing of MYBPC3
nd oligonucleotide hybridization-based DNA sequencing
f the coding regions and splice sites of the MYH7,
YBPC3, TNNT2, TNNI3, TPM1, ACTC, MYL2, MYL3,
AMP2, PRKAG2, and GLA genes with a custom-designed
ffymetrix GeneChip (Affymetrix, Santa Clara, California)
latform. Every variant identified was confirmed by direct
equencing and, whenever possible, by restriction enzyme
igestion (4). Novel mutations were considered potentially
isease-causing only if they were absent in at least 300
nrelated chromosomes from adult, ethnicity-matched,
ealthy control subjects and produced a change in a highly
onserved residue among species and isoforms (14).
tatistical methods. The prevalence of end-stage progres-
ion among our patients with triple mutations was com-
ared with that of the overall HCM population undergoing
enetic screening at our institutions (n  488) with the
isher exact test.
esults
f the 488 index patients, 251 were found to harbor at least
putative HCM-susceptibility gene mutation (51%). Of
hese, 223 had single mutations (46%) and 24 had double
utations (5%). In addition, 4 patients (0.8%) carried 3
istinct mutations, involving MYH7, MYBPC3, and TNNI3
Table 1). Three of the 4 index patients with triple muta-
ions showed early onset of severe HCM phenotype asso- (iated with marked symptoms,
entricular arrhythmias, and a
rogressive clinical course culmi-
ating in classic end-stage man-
festations. These data indicate
hat the presence of triple muta-
ions confers a relative risk of 14
95% confidence interval: 5 to
8; p  0.001) for development
f an end-stage phenotype.
atient #1. A 32-year-old woman
II-1, Fig. 1) was diagnosed with
CM at the age of 18 years after presentation with dyspnea
nd exertional angina. At the time, she had no family
istory of cardiovascular disease or sudden cardiac death. An
chocardiogram at presentation showed extreme LV hyper-
rophy (maximum LV wall thickness 32 mm) and severe LV
utflow tract obstruction (peak gradient 85 mm Hg) at rest.
t age 24 years her maximum LV wall thickness had
egressed to 27 mm, LV obstruction had spontaneously
isappeared, and there were signs of severe diastolic dys-
unction with left atrial dilation (Fig. 2). Cardiac magnetic
esonance imaging showed substantial late-gadolinium en-
ancement in the thinned portion of the basal septum,
ompatible with replacement fibrosis. During follow-up she
eveloped progressive deterioration of systolic and diastolic
unction, with recurrent angina, episodes of acute congestive
eart failure, and recurrent atrial fibrillation. A second
ardiac magnetic resonance imaging at age 30 years showed
arked increase in delayed contrast enhancement (Fig. 2),
nd positron emission tomography scan showed severe
icrovascular dysfunction (average myocardial flow after
ipyridamole infusion 1.31 ml/g/min; normal values 2.0
l/g/min). She underwent successful transcatheter ablation
f atrial fibrillation and has remained in sinus rhythm with
atisfactory hemodynamic balance on amiodarone, carve-
ilol, angiotensin-converting enzyme inhibitors, and loop
iuretics. A prophylactic implantable cardioverter-
efibrillator (ICD) with biventricular pacing capability was
ubsequently implanted.
Genetic analysis revealed heterozygous mutations in 3
istinct sarcomere genes, including a missense mutation in
YH7 (R869H), a splice site mutation in MYBPC3
E258K), and a frameshift mutation in TNNI3 (A86fs).
oth MYH7-R869H and MYBPC3-E258K have been pre-
iously reported in HCM (Genomics of Cardiovascular
evelopment, Adaptation, and Remodeling; NHLBI Pro-
ram for Genomic Applications, Harvard Medical School).
amily screening revealed the MYBPC3-E258K and
NNI3-A86fs mutations in the proband’s father (I-2,
ig. 1), a 58-year-old gentleman who had always been active
nd totally asymptomatic. His echocardiogram showed definite
CM, with LV hypertrophy prevalently localized at the apex
nd preserved LV function (Fig. 1). The proband’s mother
Abbreviations
and Acronyms
DNA  deoxyribonucleic
acid
ECG  electrocardiogram
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LV  left ventricularI-1, Fig. 1), a 52-year-old woman with a history of mild
Clinical Features of the Study Patients and Genotype-Positive Family MembersTable 1 Clinical Features of the Study Patients and Genotype-Positive Family Members
Pedigree Individual Sex
Relation to
Index Case
Genotype Age at
Enrollment
(yrs)
Age at Last
Evaluation
(yrs)
Echocardiographic Features
ECG Findings Symptoms Events/OutcomeMYH7 MYBPC3 TNNI3
Evidence
of HCM
Max LV
Thickness
(mm) Site
#1 II-1 F — R869H E258K A86fs* 18 32 Yes 32 Septum Diffuse repolarization
abnormalities, LVH
Dyspnea, palpitations,
angina
End-stage, HF, ICD
#1 II-2 M Brother — — A86fs* 28 30 No 10 — Normal None None
#1 I-1 F Mother R869H — — 52 53 Yes 16 Septum Atrial conduction
delay
Mild dyspnea None
#1 I-2 M Father — E258K A86fs* 58 59 Yes 19 Apex Diffuse T-wave
inversion, LVH
None None
#2 II-4 M — E1455X* R273C E165D* 29 46 Yes 17 Septum LVH, LVS Progressive dyspnea,
angina
End-stage, HF, ICD
#2 II-3 F Sister — — E165D* 57 58 No 8 — Normal None None
#2 I-1 M Father — R273C — 80 80 No 9 — Normal None None
#2 I-2 F Mother E1455X* — E165D* 76 78 Yes 16 Septum LVH, LVS Mild dyspnea None
#2 III-4 F Niece — — E165D* 35 38 No 8 — Normal None None
#2 III-5 M Son E1455X* — E165D* 17 19 Yes 12 Septum Small inferior
Q waves
None None
#3 II-5 F — R869H K1065fs P371R* 24 45 Yes 36 Septum LVH, T-wave inversion Progressive dyspnea Cardiac arrest,
ICD, subsequent
end-stage
#3 II-2 F Sister Unknown K1065fs† P371R*† — 29 Yes 28 Septum Unknown Unknown Died of stroke
(likely
cardioembolic)
#3 I-1 M Father — K1065fs P371R* 61 69 Yes 19 Septum Nonspecific ST–T-
wave changes
None None
#3 III-1 M Nephew — K1065fs P371R* 19 21 Yes 16 Septum Normal None None
#4 II-2 M — R1079Q — Q969X 47 54 Yes 16 Septum Left axis deviation,
nonspecific ST–T-
wave changes
Atypical chest pain None
#4 II-3 F Sister R1079Q R668H Q969X 48 50 Yes 19 Septum Normal, NSVT on
Holter
Atypical chest pain ICD
#4 III-5 F Niece R1079Q — Q969X 33 34 No 8 — Normal None None
#4 III-7 F Niece R1079Q R668H — 30 31 No 9 — Normal None None
#4 III-8 F Niece — — Q969X 29 30 No 8 — Normal None None
*Novel mutation. †Obligate carrier.
ECG  electrocardiographic; HCM  hypertrophic cardiomyopathy; HF  (congestive) heart failure; ICD  implantable cardioverter-defibrillator; LV  left ventricular; LVH  left ventricular hypertrophy; LVS  left ventricular strain; NSVT  nonsustained ventricular
tachycardia.
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April 6, 2010:1444–53 Triple Mutations in Familial HCMyspnea on effort, had mild asymmetric septal hypertrophy
ssociated with the MYH7-R869H mutation. The proband’s
rother, age 28 years (II-2, Fig. 2), only had the TNNI3-A86fs
utation and was clinically unaffected, with normal electrocar-
iogram (ECG) and echocardiographic findings.
atient #2. A 46-year-old man was diagnosed at the age of
9 years due to mild exertional dyspnea (Fig. 3). At the
ime, he had nonobstructive HCM with LV chamber
ilation and systolic function at the lower limits of normal
ejection fraction 56%). In the following years he developed
arked LV remodeling with progressive systolic dysfunc-
ion and wall-thinning in conjunction with severe symptoms
f congestive heart failure (Fig. 4). A positron emission
omography scan at age 33 years showed marked microvas-
ular dysfunction (average myocardial flow after dipyridam-
le infusion 1.06 ml/g/min (normal range 2.00 ml/g/min
n this age group). At age 39 years he received an ICD,
hich repeatedly intervened to terminate runs of sustained
entricular tachycardia. At age 43 years he required cardiac
ransplantation due to refractory heart failure. His LV cavity
easured 238 ml in diastole, and his ejection fraction was 28%.
fter transplantation he rapidly recovered and is now well.
Genetic analysis revealed 3 missense mutations, of which
TNNI3–A86fs 
MYH7–R869H 
MYBPC3–E258K
LV
LA
RV
RA
LV
LA
RV
RA
1-I
II-1
Figure 1 Pedigree of Patient #1
The index patient is indicated by the black arrows. The electropherograms show t
4-chamber view are shown for the 3 affected individuals. The white arrows indicat
vertical rectangles and the arrows indicate the double peak at the site of the ide
ventricle.were in MYH7 (R723C and E1455X) and 1 in MYBPC3 aE165D). Of these mutations, MYH7-R723C has been
escribed previously (5), whereas the premature truncation,
onsense mutation in beta myosin heavy chain (MYH7-
1455X) and MYBPC3-E165D are novel. Notably, al-
hough nonsense mutations in MYH7 have not been dem-
nstrated to be pathogenic in HCM, the 2 MYH7
utations present in this patient were inherited in trans,
ndicating that he had no normal beta-myosin heavy chain
rotein. Both novel mutations were absent in 300 unrelated
hromosomes from healthy control subjects; in addition
YBPC3-E165D changes a residue that is highly conserved
mong species. The proband’s mother (I-2, Fig. 3) was
ompound heterozygote possessing both MYH7-E1455X
nd MYBPC3-E165D but exhibited mild, nonobstructive
CM; the proband’s father (I-1, Fig. 3) had the MYH7-
723C mutation but was clinically unaffected at age 80
ears. The proband’s sister (II-3, Fig. 3), age 57 years,
nherited only her mother’s MYBPC3-E165D mutation and
as also clinically unaffected. His brother (II-2, Fig. 3) was
enotype-negative. The proband’s son (III-5, Fig. 3), age 19
ears, carried the MYH7-E1455X and MYBPC3-E165D
utations. He was asymptomatic, but his echocardiogram
howed mild asymmetric hypertrophy of the basal septum
+/-R869H
-/-E258K
-/-A86fs
-/-R869H
+/-E258K
+-A86fs
+/-R869H
+/-E258K
+/-A86fs
-/-R869H
-/-E258K
+-A86fs
1
1
2
2
LV
LA
RV
RA
I
II
2-I
tified mutations. Echocardiographic still-frames in the apical end-diastolic
site of maximum LV hypertrophy for each individual. In the panels on the left, the
mutations. LA  left atrium; LV  left ventricle; RA  right atrium; RV  righthe iden
e the
ntifiednd anterior papillary muscle, consistent with mild HCM.
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Triple Mutations in Familial HCM April 6, 2010:1444–53atient #3. A 45-year-old woman was diagnosed with
CM at the age of 24 years after resuscitation from cardiac
rrest due to documented ventricular fibrillation (Fig. 5). An
chocardiogram showed severe asymmetric LV hypertrophy
ith a maximum thickness of 36 mm at the basal septum
Fig. 6), elongated mitral leaflets without evidence of outflow
bstruction, and normal LV systolic function. During
ollow-up her echocardiograms showed progressive septal thin-
ing and a decline in LV function, with a recent evaluation
howing a basal septum of 18 mm (Fig. 6) and an LV ejection
raction of 42%. This coincided with a clinical deterioration
nd development of exertional dyspnea, despite significant
edical therapy with carvedilol, angiotensin receptor blockers,
nd diuretics. An ICD was placed for secondary prevention
fter her cardiac arrest, repeatedly replaced over the years, and
ecently upgraded to perform biventricular pacing. Of note,
ardiac resynchronization has led to significant subjective
mprovement in quality of life and exercise tolerance. During
ollow-up, however, she received 2 appropriate ICD discharges
ue to rapid sustained ventricular tachycardia.
Genetic screening showed 1 mutation in MYH7 (R869H)
nd 2 in MYBPC3 (K1065fs and P371R). Both MYBPC3-
A B
E
LV
LA
Apex
Figure 2 Evidence of Severe LV Dysfunction and Fibrosis in Pat
Echocardiographic apical 4-chamber view at end-diastole (A) and end-systole (B) s
akinetic ventricular septum, and marked left atrial (LA) dilation. Pulsed-wave Dopp
tissue Doppler velocity reduction (D) E’ 5 cm/s). Cardiac magnetic resonance ima
enhancement in the ventricular septum extending into the posterior free wall (E).1065fs and MYH7-R869H had been previously reported fGenomics of Cardiovascular Development, Adaptation, and
emodeling; NHLBI Program for Genomic Applications,
arvard Medical School). Conversely, MYBPC3-P371R was
ovel but was absent in 300 unrelated chromosomes from
ealthy control subjects and produced a change in a highly
onserved residue. Co-segregation studies in this family
howed that K1065fs and P371R are pathogenic when inher-
ted together, as in the proband’s nephew (III-1, Fig. 5). Of
ote, another unrelated index case in the Florence cohort has
een found to have both K1065fs and P371R. The proband’s
ather (I-1, Fig. 5), age 69 years, had a family history of
remature sudden death and was found to have a mild HCM
henotype, characterized by maximum septal thickness of 19
m, with preserved LV function and excellent exercise toler-
nce (maximum oxygen consumption was 32 ml/min/kg). He
arries both MYBPC3-K1065fs and MYBPC3-P371R. One of
he proband’s sisters (II-2, Fig. 5) died suddenly at the age of
1 years, possibly from cardioembolic stroke. Obligate affected
tatus for both MYBPC3 mutations could be inferred, due to
heir presence in her only child. This individual, age 21 years
III-1, Fig. 5), has a mild form of nonobstructive HCM
maximum LV wall thickness 16 mm) with preserved LV
C
D
LV
LA
Base
#1
g mild left ventricular (LV) cavity dilation with reduced ejection fraction, a bright,
wing a restrictive mitral flow pattern (C) associated with severe early diastolic
nd-diastolic short-axis images demonstrate extensive transmural late gadoliniumient
howin
ler sho
ging eunction and is asymptomatic.
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April 6, 2010:1444–53 Triple Mutations in Familial HCMatient #4. A 50-year-old woman (II-3, Fig. 7) was
iagnosed with HCM at the age of 48 years as part of
linical screening of her family. In contrast to the other 3
edigrees shown, she was not the index case in her family,
ecause the first patient identified was her brother (II-2,
ig. 7). On presentation, the patient had mild symptoms of
typical chest pain for several years. Her echocardiogram
howed moderate nonobstructive HCM with a maximum
V wall thickness of 19 mm and normal LV dimensions
nd systolic function. Although she had no history of
yncope, 24-h ambulatory ECG monitoring identified sev-
ral runs of nonsustained ventricular tachycardia (HR140
eats/min, longest run of 7 beats) (Fig. 7). She had an ICD
mplanted and has had no shocks delivered at 6-month
ollow-up.
Genetic analysis identified 3 missense mutations, of
hich 1 was in the beta myosin heavy chain (MYH7-
1079Q), and 2 were in cardiac myosin binding protein C
MYBPC3-Q969X and R668H). All 3 mutations have been
dentified in isolation in previous HCM families or pro-
ands as single, presumed pathogenic gene mutations
Genomics of Cardiovascular Development, Adaptation,
nd Remodeling; NHLBI Program for Genomic Applica-
ions, Harvard Medical School). In contrast to patient #3,
ho had MYBPC3 mutations residing on the same allele,
hese mutations were inherited in trans, as demonstrated by
-/-E1455X
+/-R723C
-/-E165D
-/-E1455X
-/-R723C
-/-E165D
+/-E165D
-/-R723C
I
II
III
1
1
1
2
2
3
3
MYH7–E1455X MYH7–R72
-/-E1455X
Figure 3 Pedigree of Patient #2
The electropherograms show the identified mutations. The thick arrow indicates th
bottom panels, the vertical rectangles and the thin arrow indicate the double peahe absence of the R668H mutation in Patient II-2 (Fig. 7). df note, that these 2 MYBPC3 mutations are in trans is
lso confirmed by their separate transmission in the patient’s
ffspring (Fig. 7).
Subsequent clinical and genetic screening of first-degree
elatives revealed that the 3 daughters of the patient (III-5,
II-7, III-8, Fig. 7)—who are ages 33, 30, and 29 years,
espectively—have inherited either 1 or 2 of the 3 mutations
dentified in their mother; nevertheless, all are asymptom-
tic and show normal ECG and echocardiograms. The
atient’s brother (the family proband, II-2, Fig. 7), age 54
ears, was diagnosed previously with mild nonobstructive
CM (maximum LV wall thickness 16 mm), and is currently
symptomatic. Genetic screening was positive for 2 of the
ister’s 3 mutations (Fig. 7).
iscussion
enetic testing in a large cohort of 488 probands with
CM allowed the identification of rare triple sarcomere
ene mutations in 4 patients (i.e., a 0.8% prevalence),
ncluding 1 with double MYH7 and a single MYBPC3
utation, 2 with a single MYH7 and double MYBPC3
utations, and 1 with single mutations in MYH7,
YBPC3, and TNNI3. To our knowledge, this is the first
eport of HCM caused by 3 independent genetic defects.
emarkably, 3 of the 4 patients with triple mutations (75%)
-/-E1455X
-/-R723C
+/-E165D
+/-E1455X
-/-R723C
+/-E165D
+/-R723C 
+/-E165D
-/-R723C
2
4
4
5
5
MYBPC3–E165D 
+/-E1455X
+/-E1455X
+/-E165D
band. In the
he site of the identified mutations.3C 
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k at teveloped an end-stage phenotype with severe LV dysfunc-
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Triple Mutations in Familial HCM April 6, 2010:1444–53ion. These 3 patients had originally presented with severe
V hypertrophy by age 25 years. In the next 10 to 20 years,
owever, they developed marked cardiac remodelling char-
cterized by restrictive physiology, atrial dilation, and sys-
olic dysfunction associated with progressive LV wall thin-
ing and fibrosis (15,16); 1 patient required cardiac
ransplantation (17). By comparison, only 29 of 488 or 6%
f the overall genotyped population with HCM seen at our
enters developed end-stage disease, similar to the preva-
ence in other reports (17,18). This suggests that triple
utations confer a 14-fold increase in risk for the develop-
ent of end-stage disease. Furthermore, all 4 probands with
riple mutations had significant ventricular arrhythmias,
rompting the implantation of a defibrillator for primary or
econdary prevention of sudden cardiac death. Notably, 1
Figure 4 Evidence of Disease Progression in Patient #2
Stop frames of echocardiograms obtained at the time of the positron emission
tomography scan (age 33 years; A, C, and E) and at final evaluation (age 42
years; B, D, and F). Comparison of the 2 echocardiograms shows progression
of left ventricular (LV) cavity enlargement and systolic impairment, with regres-
sion of septal hypertrophy. (A to D) Parasternal long-axis view. (E and F) Apical
4-chamber view. *Interventricular septum. LA  left atrium. Reproduced, with
permission, from Olivotto et al. (24).atient had been resuscitated from cardiac arrest, and snother received multiple appropriate interventions after
CD insertion (15).
Overall, the clinical course of HCM patients with triple
utations strongly supports the concept that multiple sar-
omere defects might be associated with more severe clinical
henotype and disease course (8–12,19). The TNNI3-203/
HC-403 double-mutant mouse model recently reported
y Tsoutsman et al. (10), buttresses the concept of a gene
osage effect resulting in more severe clinical phenotypes
11,12,20,21). In this model, although each mutation by
tself was linked to a hypertrophic phenotype, the presence
f both mutations rapidly led to LV dilation, severe heart
ailure, and premature death (10), echoing the development
f end-stage HCM in our cohort.
Comprehensive sarcomere mutational screening might
rovide, on the basis of the present findings, important clues
o risk stratification and potentially indicate the need for
ifferential surveillance strategies based on genotype. Young
atients with multiple mutations might benefit from close
linical and imaging follow-up to allow timely recognition
f pending end-stage progression (18). In the presence of an
nitial decline in systolic function, LV wall thinning, or
rogression of intramyocardial fibrosis, prompt initiation of
ngiotensin-converting enzyme inhibition or angiotensin
eceptor blockade might be beneficial to mitigate further
dverse remodeling and should be considered before overt
ystolic dysfunction has ensued (1,2). Furthermore, patients
ith more than 1 HCM-causing mutation might require
eightened attention with regard to sudden death risk, by
irtue of a potentially increased susceptibility to ventricular
rrhythmias (15,22).
A plausible explanation of the adverse consequences of
omplex genotypes is that multiple abnormal myofilament
roteins might result in more profound derangement of
arcomere mechanics, myocardial energetics, and cardiomyo-
yte dysfunction (23). In addition, other pathophysiological
echanisms might intervene, such as greater impairment of
icrovascular function due to adverse remodeling of the
oronary arterioles, leading to recurrent myocardial ischemia
nd replacement fibrosis (24,25). Two of our patients with
riple mutations had evidence of severe microvascular dys-
unction and blunted myocardial perfusion (24,25) preced-
ng the development of LV wall thinning and systolic
ysfunction, consistent with this hypothesis. In the patient
ho was subsequently transplanted, we were able to docu-
ent that both thinning and functional impairment were
econdary to widespread fibrotic replacement of the myo-
ardium (18).
Our pedigrees highlight the complexity inherent to the
CM disease process and challenge conventional wisdom
egarding the real clinical impact of single sarcomere gene
utations. For example, although most of our patients with
riple mutations exhibited severe phenotype and progressive
isease, Patient #4 had modest LV hypertrophy and mild
ymptoms at age 50 years. Furthermore, several adult
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xpression, despite carrying double mutations themselves.
uch a discrepancy suggests that certain DNA variants
ight not be capable of causing disease in isolation but
otentially exert modifying effects on disease expression, in
ombination with other mutations (10,12,26,27). The dem-
nstration of such a hypothesis is hindered by the objective
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Figure 6 Evidence of Disease Progression in Patient #3
Stop frames of echocardiographic 4-chamber view at end-diastole at age 28 (A) a
2 echocardiograms shows progression of left ventricular cavity enlargement with mifficulty, inherent to all genetic studies in HCM, of proving
hich of the identified sequence variants are truly patho-
enic and to what extent (12,14). However, the striking
henotypic expression and markedly increased prevalence of
nd-stage remodelling observed in our cohort indicate that
he multiplicity of variants importantly contributed to dis-
ase pathogenesis and clinical outcome.
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CM associated with triple sarcomere gene mutations is
are but often associated with adverse outcomes, including a
emarkably increased risk of developing end-stage disease
rogression and high prevalence of ventricular arrhythmias.
hese findings support the theory that multiple sarcomere
efects confer an increased risk of disease progression and
dverse outcome in HCM. Therefore, comprehensive ge-
etic testing might provide important insights into risk
tratification and potentially indicate the need for differen-
ial surveillance strategies based on genotype.
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Thick arrow  proband. (A) Ambulatory electrocardiographic tracing showing a 7-b0134 Firenze, Italy. E-mail: olivottoi@aou-careggi.toscana.it.EFERENCES
1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA
2002;287:1308–20.
2. Maron BJ, McKenna WJ, Danielson GK, et al. American College of
Cardiology/European Society of Cardiology clinical expert consensus
document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;
42:1687–713.
3. Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Yield
of genetic testing in hypertrophic cardiomyopathy. Mayo Clin Proc
2005;80:739–44.
4. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene
mutation screening and outcome of patients with hypertrophic cardio-
myopathy. Mayo Clin Proc 2008;83:630–8.
5. Richard PP, Charron P, Carrier L, et al., for the EUROGENE Heart
Failure Project. Hypertrophic cardiomyopathy: distribution of disease
genes, spectrum of mutations, and implications for a molecular
diagnosis strategy. Circulation 2003;107:2227–32.
6. Erdmann J, Daehmlow S, Wischke S, et al. Mutational spectrum in a
large cohort of unrelated consecutive patients with hypertrophic
cardiomyopathy. Clin Genet 2000;64:339–49.
7. Van Driest SL, Ellsworth EG, Ommen SR, et al. Prevalence and
le mutation was the sister of the proband.
n of nonsustained ventricular tachycardia at 142 beats/min.ith trip
eat ruspectrum of thin filament mutations in an outpatient referral popula-
tion with hypertrophic cardiomyopathy. Circulation 2003;108:445–51.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
K
1453JACC Vol. 55, No. 14, 2010 Girolami et al.
April 6, 2010:1444–53 Triple Mutations in Familial HCM8. Van Driest SL, Vasile VC, Ommen SR, et al. Myosin binding protein
C mutations and compound heterozygosity in hypertrophic cardiomy-
opathy. J Am Coll Cardiol 2004;44:1903–10.
9. Alpert NR, Mohiddin SA, Tripodi D, et al. Molecular and phenotypic
effects of heterozygous, homozygous, and compound heterozygote
myosin heavy-chain mutations. Am J Physiol Heart Circ Physiol
2005;288:H1097–102.
0. Tsoutsman T, Kelly M, Ng DC, et al. Severe heart failure and early
mortality in a double-mutation mouse model of familial hypertrophic
cardiomyopathy. Circulation 2008;117:1820–31.
1. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C.
Compound and double mutations in patients with hypertrophic
cardiomyopathy: implications for genetic testing and counselling.
J Med Genet 2005;42:e59.
2. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular
disease: a marker of disease severity. Circ Cardiovasc Genet 2009;2:
182–90.
3. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular
outflow tract obstruction on clinical outcome in hypertrophic cardio-
myopathy. N Engl J Med 2003;348:295–303.
4. Clinical Molecular Genetics Society (CMGS). Practice guidelines for
the interpretation and reporting of unclassified variants (UVs) in
clinical molecular genetics. Available at: http://www.cmgs.org/BPGs/
pdfs%20current%20bpgs/UV%20GUIDELINES%20ratified.pdf. Ac-
cessed October 28, 2009.
5. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-
defibrillators and prevention of sudden cardiac death in hypertrophic
cardiomyopathy. JAMA 2007;298:405–12.
6. Yacoub MH, Olivotto I, Cecchi F. ‘End-stage’ hypertrophic cardio-
myopathy: from mystery to model. Nat Clin Pract Cardiovasc Med
2007;4:232–3.
7. Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution
of hypertrophic cardiomyopathy: prevalence, incidence, risk factors,
and prognostic implications in pediatric and adult patients. J Am Coll
Cardiol 2005;46:1543–50. c8. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile,
and significance of left ventricular remodeling in the end-stage phase
of hypertrophic cardiomyopathy. Circulation 2006;114:216–25.
9. Hilfiker-Kleiner D, Knöll D. Disease-modifying mutations in familial
hypertrophic cardiomyopathy: complexity from simplicity. Circulation
2008;117:1775–7.
0. Ho CY, Seidman CE. A contemporary approach to hypertrophic
cardiomyopathy. Circulation 2006;113:e858–62.
1. Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin
Cardiol 2008;23:199–205.
2. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency
of arrhythmias in hypertrophic cardiomyopathy in relation to delayed
enhancement on cardiovascular magnetic resonance. J Am Coll Car-
diol 2008;51:1369–74.
3. Belus A, Piroddi N, Scellini B, et al. The familial hypertrophic
cardiomyopathy-associated myosin mutation R403Q accelerates ten-
sion generation and relaxation of human cardiac myofibrils. J Physiol
2008;586:3639–44.
4. Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvas-
cular flow impairment to long-term remodeling and systolic dysfunc-
tion in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:
1043–8.
5. Sotgia B, Sciagrà R, Olivotto I, et al. Spatial relationship between
coronary microvascular dysfunction and delayed contrast enhancement
in patients with hypertrophic cardiomyopathy. J Nucl Med 2008;49:
1090–6.
6. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the
genetic determinants of clinical disease expression. Nat Clin Pract
Cardiovasc Med 2008;5:747.
7. Ho CY, Lever HM, DeSanctis R, Farver CF, Seidman JG, Seidman
CE. Homozygous mutation in cardiac troponin T: implications for
hypertrophic cardiomyopathy. Circulation 2000;102:1950–5.
ey Words: complex genotypes y genetics y hypertrophic
ardiomyopathy y outcome.
